Evoke Pharma Inc. [NASDAQ: EVOK] traded at a low on 01/15/21, posting a -4.47 loss after which it closed the day’ session at $2.78. The company report on January 14, 2021 that Evoke Pharma Announces Pricing of Public Offering of Common Stock.
Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be $12.5 million. Evoke has granted the underwriter a 45-day option to purchase up to 750,000 additional shares of its common stock. The offering is expected to close on or about January 19, 2021, subject to satisfaction of customary closing conditions.
Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering.
The results of the trading session contributed to over 919443 shares changing hands. Over the past one week, the price volatility of Evoke Pharma Inc. stands at 15.09% while the volatility over the past one month is 9.78%.
The market cap for EVOK stock reached $76.81 million, with 26.15 million shares outstanding and 25.36 million shares in the current float. Compared to the average trading volume of 305.67K shares, EVOK reached a trading volume of 919443 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Evoke Pharma Inc. [EVOK]?
H.C. Wainwright have made an estimate for Evoke Pharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 22, 2020. The new note on the price target was released on March 05, 2019, representing the official price target for Evoke Pharma Inc. stock. Previously, the target price had yet another drop from $10 to $5, while B. Riley FBR Inc. kept a Buy rating on EVOK stock.
The Average True Range (ATR) for Evoke Pharma Inc. is set at 0.26
How has EVOK stock performed recently?
Evoke Pharma Inc. [EVOK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.17. With this latest performance, EVOK shares dropped by -2.80% in over the last four-week period, additionally sinking by -27.13% over the last 6 months – not to mention a rise of 73.75% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVOK stock in for the last two-week period is set at 47.76, with the RSI for the last a single of trading hit 51.35, and the three-weeks RSI is set at 45.26 for Evoke Pharma Inc. [EVOK]. The present Moving Average for the last 50 days of trading for this stock 3.01, while it was recorded at 2.75 for the last single week of trading, and 3.30 for the last 200 days.
Evoke Pharma Inc. [EVOK]: Deeper insight into the fundamentals
Return on Total Capital for EVOK is now -167.47, given the latest momentum, and Return on Invested Capital for the company is -169.54. Return on Equity for this stock declined to -169.54, with Return on Assets sitting at -118.22. When it comes to the capital structure of this company, Evoke Pharma Inc. [EVOK] has a Total Debt to Total Equity ratio set at 3.16. Additionally, EVOK Total Debt to Total Capital is recorded at 3.07, with Total Debt to Total Assets ending up at 2.17.
Reflecting on the efficiency of the workforce at the company, Evoke Pharma Inc. [EVOK] managed to generate an average of -$1,425,131 per employee.Evoke Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.
Earnings analysis for Evoke Pharma Inc. [EVOK]
With the latest financial reports released by the company, Evoke Pharma Inc. posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EVOK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Evoke Pharma Inc. go to 40.00%.
Insider trade positions for Evoke Pharma Inc. [EVOK]
There are presently around $5 million, or 15.00% of EVOK stock, in the hands of institutional investors. The top three institutional holders of EVOK stocks are: VANGUARD GROUP INC with ownership of 1,033,707, which is approximately 57.355% of the company’s market cap and around 2.60% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 154,039 shares of the stock with an approximate value of $0.43 million in EVOK stocks shares; and BLACKROCK INC., currently with $0.36 million in EVOK stock with ownership of nearly -35.679% of the company’s market capitalization.
Positions in Evoke Pharma Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 14 institutional holders increased their position in Evoke Pharma Inc. [NASDAQ:EVOK] by around 611,909 shares. Additionally, 7 investors decreased positions by around 149,621 shares, while 9 investors held positions by with 1,101,453 shares. The mentioned changes placed institutional holdings at 1,862,983 shares, according to the latest SEC report filing. EVOK stock had 10 new institutional investments in for a total of 159,255 shares, while 3 institutional investors sold positions of 42,216 shares during the same period.